Smoking and cardiovascular diseases

1. Adam, B., Cetinkaya, F., Malatyahoglu, E., Gurses, N. Cigarette smoking and lipid and lipoproteins in cord plasma. Jpn. Heart. J. 1993, 34, p. 759-762.

2. Anand, S.S., Islam, S., Rosengren, A. et al. Risk factors for myocardial infarction in women and men; insights from the INTERHEART study. Eur. Heart. J. 2008, 29, p. 932-940.

3. Benowitz, N.L.  Pharmacologic aspects of cigarette smoking and nicotine addiction. N. Eng. J. Med. 1988, 319, p. 1318-1330.

4. Berg, G., Mesch, V., Boero, L. et al. Lipid and lipoprotein profile in menopausan transition. Effects of hormones, age and fat distribution. Horm. Metab. Res. 2004, 36, p. 215-220.

5. Bielicki, J.K., Mc Call, M.R., Van den Berg, J.J. et al. Copper and gas-phase cigarette smoke inhibit plasma lecithin: cholesterol acyltransferase activity by different mechanisms. J. Lipid. Res. 1995, 36, p. 322-331.

6. Block, G., Jensen, C., Dietrich, M. et al. Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. J. Am. Coll. Nutr. 2004, 23, p. 141-147.

7. Bloomer, R.J., Solis, A.D., Fisher-Wellman, K.H., Smith, W.A. Postprandial oxidative stress is exacerbated in cigarette smokers. Br. J. Nutrition 2008, 99, p. 1055-1060.

8. Brown, M.S., Goldstein, J.L. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Res. Biochem. 1983, 52, p. 223-261.

9. Campbell, S.Ch., Moffatt, R.J., Stamford, B.A. Smoking and smoking cessation – the relationship between cardiovascular disease and lipoprotein metabolism: A review. Atherosclerosis 2008, 201(2), p. 225-235.

10. Craig, W.Y., Palomaki, G.E., Haddow, J.E. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Br. Med. J. 1989, 298, p. 784-788.

11. Doll, R., Hill, J.B. The mortality of doctors in relation to their smoking habits. Br. Med. J. 1954, 1, p. 1451-1455.

12. Doll. R., Peto, R., Boreham, J., Sutherland, I. Mortaliry in relation to smoking: 50 years´ observations on male British doctors. Br. Med. J. 2004, 328, p. 1519-1528.

13. Eliasson, B., Attvall, S., Taskinen, M.R., Smith, U. The insulin resistance syndrome in smokers is related to smoking habits. Arteriosc. Thromb. 1994, 14, p. 1946-1950.

14. Esterbauer, H., Schaur, R.J., Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol. Med. 1991, 11, p. 81-128.

15. Fraser, R., Clark, S.A., Rey, W.A., Murray, F.E. Nicotine decreases the porosity of rat liver: a possible mechanism for hypercholesterolemia. Br. J. Exp. Pathol. 1988, 69, p. 345-350.

16. Freeman, D.J., Caslake, M.J., Griffin, B.A. et al. The effect of smoking on post-heparin lipoprotein and hepatic lipase, cholesterol ester transfer protein and lecithin-cholesterol acyl transferase activities in human plasma. Eur. J. Clin. Invest. 1998, 28, p. 584-591.

17. Girdhar, G., Xu, S., Jesty, J., Bluestein, D. In vitro model of platelet-endothelial activation due to cigarette smoke under cardiovascular circulation conditions. Ann. Biomed. Engineering 2008, 36(7): p. 1142-1151.

18. Girdhar, G., Xu, S., Jesty, J., Bluestein, D. Reduced nicotine cigarettes increase platelet activation in smokers in vivo: a dilemma in harm reduction. Nicotine Tob. Res. 2008, 10(12): p. 1737-1744.

19. Goldhaber, S.Z., Grodstein, F., Stampfer, M.J. et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997, 277, p. 642-645.

20. Goldhaber, S.Z., Savage, D.D., Garrison, R.J. et al. Risk factors for pulmonary embolism. The Framingham Study. Am. J. Med. 1983, 74, p. 1023-1028.

21. Hansson, P.O., Eriksson, H., Welin, L. et al. Smoking and abdominal obesity: Risk factors for venous thrombolism among middle-aged men: „The study of men born in 1913“. Arch. Intern. Med. 1999, 159, p. 1886-1890.

22. Hellerstein, M.K., Benowitz, N.L., Neese, R.A. et al. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J. Clin. Invest. 1994, 93, p. 265-272.

23. Hogg, N., Kalyanaraman, B. Nitric oxide and lipid peroxidation. Review. Biochem. Biophys. Acta 1999, 1411, p. 378-384.

24. Hunter, K.A., Garlick, P.J., Broom, I. et al. Effects of smoking and absention from smoking on fibrinogen synthesis in humans. Clin. Sci. (Lond), 2001, 100, p. 459-465.

25. Chávez, J., Cano, C., Souki, A. et al. Effect of cigarette smoking on the oxidant/ antioxidant balance in healthy subjects. Am. J. Therapeut. 2007, 14(2), p. 189-193.

26. Chen, C., Lo, G. Cigarette smoke extract inhibits oxidative modification of low density lipoprotein. Atherosclerosis 1995, 112, p. 177-185.

27. Chrette-Brown, J., Mulligan, J., Doyle, K. et al. Oral nicotine induces on atherogenic lipoprotein profile. Proc. Soc. Exp. Biol. Med. 1986, 182, p. 409-413.

28. Iscan, A., Yigrroglu, M.R., Ece, A. et al. The effect of cigarette smoking during pregnancy on cord blood lipid, lipoprotein and apolipoprotein levels. Jpn. Heart J. 1997, 38, p. 497-502.

29. Kannel, W.B., Levy, D. Menopause, hormones, and cardiovascular vulnerability in women. Arch. Intern. Med. 2004, 164, p. 479-481.

30. Kalyanaraman, B., Gutterman, D. Prologue: vascular effects of free radicals. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, p. 2253-2254.

31. Kinlay, S., Dobson, A.J., Heller, R.F. et al. Lipid and apolipoprotein levels in an Australian community. Med. J. Aust. 2001, 154, p. 170-175.

32. Klein, J.A., Ackerman, S.L. Oxidative stress, cell cycle, and neurodegeneration. Review. J. Clin. Invest. 2003, 111, p. 785-793.

33. Kodama, M., Kaneko, M., Aida, M. et al. Free radical chemistry of cigarette smoke and its implication in human cancer. Anticancer Res. 1997, 17, p. 433-437.

34. Lang, N.N., Guomundsdóttir, I.J., Bonn, N.A. et al. Marked impairment of Protease-Activated Receptor type 1 – mediated vasodilatation and fibrinolysis in cigarette smokers. J. Am. Coll. Cardiol. 2008, 52, p. 33-39.

35. Lawlor, D.A., Ebrahim, S., Davey- Smith, G. Sex matters: secular and geographical trends in sex differences in coronary heart disease mortality. BMJ 2001, 323, p. 541-545.

36. Mackay, J., Eriksen, M., Shafey, O. The Tobacco Atlas. Atlanta, Georgia: American Cancer Society, 2006. 128 s.

37. Maeda, K., Noguchi, Y., Fukui, T. The effect of cessation from cigarette smoking on the lipid and lipoproteins profiles: a meta-analysis. Prev. Med. 2003, 37, p. 283-290.

38. Mahley, R.W., Rall, S.C. Jr. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Gen. 2000, 1, p. 507-537.

39. Mc Hill, H.C. Smoking and the pathogenesis of atherosclerosis. Adv. Exp. Med. Biol. 1990, 273, p. 9-16.

40. Mjos, O.D. Lipid effects of smoking. Am. Heart J. 1988, 115, p. 272-275.

41. Miller, G.J., Bauer, K.A., Cooper, J.A., Rosenberg, R.D. Activation of the coagulant pathway in cigarette smokers. Thromb. Haemost. 1998, 79, p. 549-553.

42. Moffatt, R.J., Biggerstaff, K.D., Stamfond, B.A. Effects of the transdermal nicotine patch on normalization of HDL-C and its subfractions. Prev. Med. 2000, 31, p. 148-152.

43. MRFIT Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Prev. Med. 1986, 15, p. 254- 260.

44. Premkumar, K., Bowlus, C.L. Ascorbic acid does not increase the oxidative stress induced by dietary iron in C3H mice. J. Nutr. 2004, 134, p. 435-438.

45. Ruhle, W., Graf von Ballestrem, C.L., Pult, H.M., Gnirs, J. Correlation in cotinine levels in amniotic fluid, umbilical artery blood and maternal blood. Geburtshilfe Frauenheilkd 1995, 55, s. 156-159.

46. Samarma, M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The Sinus study. Arch. Int. Med. 2000, 160, p. 3415-3420.

47. Shao, B., O´Brien, K.D., McDonald, T.O. et al. Acrolein modifies apolipoprotein A-1 line in the human artery wall. Ann. N.Y. Acad. Sci. 2005, 1043, p. 396-403.

48. Sinha, S., Luben, R.N., Weich, A. et al. Fibrinogen and cigarette smoking in men and women in the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population. Eur. J. Cardiovasc. Prev. Rehabil. 2005, 12, p. 144-150.

49. Slow, R.C.M., Sato, H., Mann, G.E. Heme oxygenase carbon monoxide signaling pathway in atherosclerosis: antiatherogenic actions of bilirubin and carbon monoxide. Cardiol. Res. 1999, 41, p. 385-394.

50. Stampfer, M.J., Hu, F.B., Manson, J.E. et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N. Engl. J. Med. 2000, 343, p. 16-22.

51. Stocker, R., Keaney, J.F. Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2003, 84, p. 1381-1478.

52. Sytkowski, P.A., D´Agostino, R.B., Belanger, A., Kannel, W. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study 1950-1989. Am. J. Epidemiol. 1996, 143, p. 338- 350.

53. Tamamizu-Kato, Sh., Wong, J.Y., Jairam, V. et al. Modification by acrolein, a component of tobacco smoke and age-related oxidative stress, mediates functional impairment of human apolipoprotein E. Biochemistry 2007, 46(28), p. 8392–8400.

54. US Department of Health and Human Services. The health consequences of smoking: cardiovascular disease. A report of Surgeon General. Rockville, MD. US Public Health Services, 1983. DHHS Publication DHS 84-50204.

55. Van Eken, B.E., den Heijer, M., Bos, G.M.J. et al. Recurrent venous thrombosis and markers of inflammation. Thromb. Haemost. 2000, 83, p. 536-539.

56. Van Hylckama- Vlieg, A., Rosendaal, F.R. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J. Thromb. Haemost. 2003, 1, p. 2677-2678.

57. Wang, W., Ballatori, N. Endogenous glutathione conjugates: occurence and biological function. Review. Pharmacol. Rev. 1998, 50, p. 335-356.

58. Watanabe, K., Eto, K., Furuno, K. et al. Effect of cigarette smoke on lipid peroxidation and liver function tests in rats. Acta. Med. Okayama 1995, 49, p. 271-274.

59. Waters, D., Lesperance, J., Gladstone, P. et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1996, 94, p. 614-621.